Royalty Pharma (RPRX) FCF Margin Growth (1y) (2020 - 2026)
Powered by 
Analysis
Royalty Pharma (RPRX) FCF Margin Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -89.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1,183.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 26,102.00 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 869.00 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 769.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 811.00 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 19,111.00 |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | 2,747.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 811.00 |
| Mar 31, 2026 | -6,255.00 |
| Dec 31, 2025 | -2,643.00 |
| Sep 30, 2025 | 4,439.00 |
| Jun 30, 2025 | 7,582.00 |
| Mar 31, 2025 | 285.00 |
| Dec 31, 2024 | 7,998.00 |
| Sep 30, 2024 | -10,976.00 |
| Jun 30, 2024 | -11,481.00 |
| Mar 31, 2024 | 3,868.00 |
| Dec 31, 2023 | -9,503.00 |
| Sep 30, 2023 | 15,840.00 |
| Jun 30, 2023 | 2,708.00 |
| Mar 31, 2023 | -1,870.00 |
| Dec 31, 2022 | 123.00 |
| Sep 30, 2022 | 1,231.00 |
| Jun 30, 2022 | 1,137.00 |
| Mar 31, 2022 | 7,786.00 |
| Dec 31, 2021 | 9,713.00 |
| Sep 30, 2021 | -9,335.00 |